Research Analysts Set Expectations for SPRY Q3 Earnings

Key Points

• Roth Capital forecasts ARS Pharmaceuticals will report Q3 2025 earnings per share of ($0.44), maintaining a "Buy" rating with a price target of $40.00.
• The company recently announced a Q2 loss of ($0.46) EPS, missing expectations, but had revenue of $15.72 million, surpassing estimates of $12.92 million.
• Insider trading activity showed CFO Kathleen D. Scott sold shares significantly, reducing her position by 55.45%, raising questions about management sentiment towards the stock.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at Roth Capital issued their Q3 2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a report released on Thursday, September 4th. Roth Capital analyst J. Wittes forecasts that the company will post earnings of ($0.44) per share for the quarter. Roth Capital currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals' Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.63) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.77 EPS, FY2028 earnings at $2.06 EPS and FY2029 earnings at $4.06 EPS.

Separately, Wall Street Zen downgraded shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $32.50.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY traded down $0.12 during trading on Monday, reaching $10.03. 2,273,759 shares of the stock were exchanged, compared to its average volume of 3,001,979. ARS Pharmaceuticals has a 12 month low of $9.79 and a 12 month high of $18.90. The firm has a market cap of $991.26 million, a PE ratio of -20.47 and a beta of 0.87. The stock has a 50-day moving average price of $15.27 and a 200-day moving average price of $14.32. The company has a current ratio of 6.17, a quick ratio of 5.98 and a debt-to-equity ratio of 0.37.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%.The firm had revenue of $15.72 million for the quarter, compared to the consensus estimate of $12.92 million.

Insiders Place Their Bets

In related news, insider Eric Karas sold 15,000 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $16.00, for a total value of $240,000.00. Following the sale, the insider owned 7,696 shares of the company's stock, valued at $123,136. The trade was a 66.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn sold 740,149 shares of the business's stock in a transaction on Friday, June 27th. The stock was sold at an average price of $18.46, for a total transaction of $13,663,150.54. Following the completion of the sale, the insider directly owned 4,887,254 shares in the company, valued at approximately $90,218,708.84. This represents a 13.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 882,649 shares of company stock worth $15,773,760. Company insiders own 33.50% of the company's stock.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its position in shares of ARS Pharmaceuticals by 7.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 368,556 shares of the company's stock worth $4,636,000 after purchasing an additional 24,385 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in ARS Pharmaceuticals during the 1st quarter valued at $189,000. Alliancebernstein L.P. raised its holdings in ARS Pharmaceuticals by 1.1% during the 1st quarter. Alliancebernstein L.P. now owns 3,922,805 shares of the company's stock valued at $49,349,000 after acquiring an additional 42,071 shares during the period. Trexquant Investment LP increased its holdings in shares of ARS Pharmaceuticals by 78.2% in the first quarter. Trexquant Investment LP now owns 100,769 shares of the company's stock worth $1,268,000 after purchasing an additional 44,206 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in ARS Pharmaceuticals by 4.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 60,294 shares of the company's stock worth $636,000 after acquiring an additional 2,670 shares in the last quarter. Institutional investors own 68.16% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.